Physician profile
Michael Tsovko
NPI 1447933502
$5,110.21
in general payments reported to CMS, 2019-2025
16 companies · $3,026 in 2025
The $3,026 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,084 · 2025: $3,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,999 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,998.72 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $749.61 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $743.09 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $645.19 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $490.71 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $391.67 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $369.90 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $327.80 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $310.03 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $307.83 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $275.85 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $209.64 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $139.73 | 2025 | Spravato, Invega Sustenna |
| Biogen, INC. | $73.32 | 2024-2025 | Zurzuvae, Vumerity |
| Orexo US, INC. | $39.64 | 2024 | Zubsolv |
| Indivior INC. | $19.91 | 2024 | Perseris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $16.29 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tsovko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.